Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11684-015-0384-0 http://scihub22266oqcxt.onion/10.1007/s11684-015-0384-0 C4567274!4567274!25676019     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Med 2015 ; 9 (2): 173-86 Nephropedia Template TP {{tp|p=25676019|t=2015. Metformin and metabolic diseases: a focus on hepatic aspects |pdf=|usr=}}{{25676019}} gab.com Text Metformin and metabolic diseases: a focus on hepatic aspects JO: Front Med http://www.kidney.de/pget.php?&tw=1&pmid=25676019 #FOAvip Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibits glycogenolysis, which is a pathway that critically contributes to elevated HGP. While generating beneficial effects on hyperglycemia, metformin also improves insulin resistance and corrects dyslipidemia in patients with T2D. These beneficial effects of metformin implicate a role for metformin in managing non-alcoholic fatty liver disease. As supported by the results from both human and animal studies, metformin improves hepatic steatosis and suppresses liver inflammation. Mechanistically, the beneficial effects of metformin on hepatic aspects are mediated through both adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. In addition, metformin is generally safe and may also benefit patients with other chronic liver diseases. Twit Text FOAVip Metformin and metabolic diseases: a focus on hepatic aspects ????Front Med http://www.kidney.de/pget.php?&tw=1&pmid=25676019 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25676019 #FOAvip English Wikipedia <ref>{{Cite pmid|25676019}}</ref> Metformin and metabolic diseases: a focus on hepatic aspects #MMPMID25676019 Zheng J; Woo SL; Hu X; Botchlett R; Chen L; Huo Y; Wu C Front Med 2015[Jun]; 9 (2): 173-86 PMID25676019show ga Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibits glycogenolysis, which is a pathway that critically contributes to elevated HGP. While generating beneficial effects on hyperglycemia, metformin also improves insulin resistance and corrects dyslipidemia in patients with T2D. These beneficial effects of metformin implicate a role for metformin in managing non-alcoholic fatty liver disease. As supported by the results from both human and animal studies, metformin improves hepatic steatosis and suppresses liver inflammation. Mechanistically, the beneficial effects of metformin on hepatic aspects are mediated through both adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. In addition, metformin is generally safe and may also benefit patients with other chronic liver diseases. äMetformin and metabolic diseases: a focus on hepatic aspects (epmc).pdf DeepDyve Pubget Overpricing